Real World Evidence for MedTech Startups: Insights from Ian Weimer
For early-stage medtech companies, proving value often comes long before a product is built. In this conversation, Ian Weimer shares how real world evidence is shifting from a niche capability to essential infrastructure, and what that means for founders building in a changing regulatory and funding environment.